Bladder Cancer Coverage from Every Angle

Recent News

ASCO 2022: Tislelizumab Plus Nab-Paclitaxel Under Study in Urothelial Bladder Cancer
ASCO 2022: Focus of SWOG S1937 in Metastatic Urothelial Carcinoma Is Eribulin With or Without Gemcitabine
ASCO 2022: COSMIC-021 Cohorts of Cabozantinib Plus Atezolizumab in Urothelial Cancer
ASCO 2022: 2-Year Follow-up on Enfortumab Vedotin for Urothelial Cancer
ASCO 2022: Can N-803 Plus BCG Improve Outcomes in Non–Muscle-Invasive Bladder Cancer?
ASCO 2022: Can Cell-Free DNA Methylation Predict Chemotherapy Benefit in Bladder Cancer?
ASCO 2022: Neoadjuvant Targeting of PD-1 Plus SBRT in Muscle-Invasive Bladder Cancer
ASCO 2022: Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Bladder Cancer
Gene-Targeted Therapy for Urothelial Cancer: Study Explores Obstacles to Its Use
Photodynamic Diagnosis May Assist Surgeons With Transurethral Resection of Bladder Cancer
Student Gives Back to Former Teacher Facing Bladder Cancer Diagnosis
Pentafecta Criteria Under Evaluation After Laparoscopic Radical Cystectomy
Radical Cystectomy for Nonmetastatic Bladder Cancer: Robot-Assisted Versus Open Surgery
Predicting Response to Bladder Cancer Treatment With COXEN Analysis
Can Artificial Intelligence–Based Tool Help to Assess Treatment Response in Bladder Cancer?
Trial of Intravesicular Adenovirus Vector Therapy in Bladder Cancer Unresponsive to BCG
How Does STAG2 Promote Invasion of Muscle-Invasive Bladder Cancer?
Can Three-Gene Biomarkers Predict the Severity of Bladder Cancer?
AACR 2022: Tumor-Specific Second-Generation Imidazolium Compounds Under Study in Bladder Cancer
AACR 2022: Use of Novel Tissue Assays to Predict Therapeutic Response in Bladder Cancer
AACR 2022: Phase II Trial of Pembrolizumab Combined With Oncolytic Vaccine in Bladder Cancer
AACR 2022: KEYNOTE-992 to Study Pembrolizumab Plus Chemoradiotherapy for Bladder Cancer
AACR 2022: Can an Antidepressant Suppress Progression of Muscle-Invasive Bladder Cancer?
AACR 2022: Use of Tumor-Derived DNA From Urine and Plasma Samples to Predict Outcomes in Bladder Cancer
AACR 2022: Prognostic Value of Cathepsin L in Urinary Bladder Cancer
Phase II INSPIRE Study: Can Chemoradiation Plus Durvalumab Improve Outcomes in Bladder Cancer?
Phase III Trial to Study Triplet Immunotherapy Regimen in Bladder Cancer
Intravesical Stimulation of IL-15 Plus BCG in Bladder Cancer
Evaluating Adjuvant Infigratinib in Bladder Cancer With FGFR3 Alterations
Erdafitinib Plus Enfortumab Vedotin-ejfv Under Study in Metastatic Urothelial Cancer
STRONG Trial: Durvalumab Monotherapy for Urinary Tract Carcinoma
Double Antibody-Drug Conjugate Trial Enrolling in Metastatic Bladder Cancer
Anti–PD-L1 Therapy With PARP Inhibitor Focus of Phase II Trial in Urothelial Cancer
Radical Cystectomy Versus Trimodal Therapy for Muscle-Invasive Bladder Cancer
Using Artificial Intelligence to Identify Status of Muscle Invasion in Bladder Cancer
Maintenance Rucaparib After Chemotherapy for Metastatic Urothelial Cancer
ASCO GU 2022: Nivolumab Treatment of Urothelial Cancer With Low Expression of PD-L1
Is Ferroptosis Associated With Bladder Cancer?
ASCO GU 2022: Interim Trial Results With Pembrolizumab Plus Sacituzumab Govitecan-hziy in Urothelial Cancer
ASCO GU 2022: Neoadjuvant Therapy With Enfortumab Vedotin-ejfv in Bladder Cancer
ASCO GU 2022: Use of Gene-Expression Model to Predict Survival Outcomes in Bladder Cancer
ASCO GU 2022: Gemcitabine and Cisplatin as Neoadjuvant Therapy for Urothelial Cancer
ASCO GU 2022: Does Adding Niraparib to Best Supportive Care Improve Survival in Advanced Urothelial Cancer?
A Novel Therapeutic Target Identified for Bladder Cancer?
Geospatial Urothelial Carcinoma Hotspots and Environmental Risk Factors
Long-Term Update on Treatment With Erdafitinib in Advanced Urothelial Carcinoma
Fox Chase Researcher Receives ASCO Merit Award for Microbiome Research in Bladder Cancer
What Is the Ideal Number of Neoadjuvant Chemotherapy Cycles for Muscle-Invasive Bladder Cancer?
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: The Debate Continues
Successful Treatment of Rare Case of Urothelial Carcinoma of the Fossa Navicularis
Independent Risk Factors of Bladder Cancer: Perspective From an Iranian Province
Predicting Pathologic Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.